Truist Securities Upgrades Biogen (BIIB) to Buy
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.03 +4.96%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 50
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 50
Join SI Premium – FREE
Truist Securities analyst Danielle Brill upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $199.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Starts Arrowhead Pharma (ARWR) at Buy
- UniFirst Corp (UNF) Declares $0.365 Quarterly Dividend; 0.5% Yield
- Phoenix Education Partners names Robert Brackenbury to its board
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
